Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751381 | 0.93 | MAOA (0.38) | MAOAALDH1A1HPGDXBP1KMT2A | |
| SCHEMBL30514739 | 0.93 | MAOA (0.38) | MAOAALDH1A1HPGDXBP1KMT2A | |
| SCHEMBL21751407 | 0.90 | MAOA (0.34) | MAOAALDH1A1HPGDKMT2ATP53 | |
| SCHEMBL21767317 | 0.88 | MAOA (0.36) | MAOAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21751395 | 0.88 | LTB4R (0.40) | MAOAALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL30800137 | 0.88 | LTB4R (0.40) | MAOAALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL21751333 | 0.88 | MAOA (0.35) | MAOAALDH1A1HPGDXBP1KMT2A | |
| SCHEMBL21751418 | 0.88 | SMN1; SMN2 (0.39) | MAOAALDH1A1HPGDKMT2ATP53 | |
| SCHEMBL30800205 | 0.88 | SMN1; SMN2 (0.39) | MAOAALDH1A1HPGDKMT2ATP53 | |
| SCHEMBL21751347 | 0.87 | MAOA (0.34) | MAOAALDH1A1HPGDXBP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3841173-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| WO-2020041579-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAOA 3004/4885NPY5R 2348/4885ALDH1A1 3541/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | MAOA 3004/4885NPY5R 2348/4885ALDH1A1 3541/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAOA 3004/4885NPY5R 2348/4885ALDH1A1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.